Do new, prospective data mean the 4KScore test is “proven” for use in prime time?

According to data from a large, prospective, multi-institutional trial carried out here in the USA, the 4KScore test has shown a high degree of ability to accurately identify men with a Gleason score of 3 + 4 = 7 or higher which was subsequently confirmed on prostate biopsy. … READ MORE …

A rising incidence of intermediate- and higher-risk prostate cancer … but what does this mean?

According to another paper to be presented at the Genitourinary Cancers Symposium in Orlando, Florida, that started this morning, there was a 6 percent increase in the proportion of patients being diagnosed with intermediate- or higher-risk prostate cancers between 2011 and 2013. … READ MORE …

The optimization of risk assessment for management of prostate cancer

According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of strategies for assessing prostate cancer risk and subsequent treatment, when this is needed. … READ MORE …

Will “Apifiny” be helpful in the diagnosis of prostate cancer?

The development-stage test known as Apifiny is a new type of test that its creators believe will help in the more accurate diagnosis of prostate cancer. Whether that is actually the case seems to be rather less certain as yet. … READ MORE …

James Mohler talks prostate cancer on CureTalk

On Tuesday this week, Dr. James L. Mohler of Roswell Park Cancer Institute participated in an hour-long discussion on key issues related to the diagnosis and management of early stage prostate cancer. … READ MORE …

The value of the PCA3 test: a multi-center study

The prostate cancer antigen 3 or PCA3 test was initially approved as an aid to the assessment of risk of prostate cancer in men with an elevated PSA level who had already been given at least one prior, negative biopsy. … READ MORE ..

cfDNA from blood samples as a way to measure prostate cancer risk

According to a new article in the journal Clinical Chemistry, an international research team believes they have found a completely new way to test for risk of prostate cancer by measuring tumor-specific, cell-free DNA (cfDNA) in blood samples (serum and plasma). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,261 other followers